EMSOS studies planned/ ongoing
Chondrosarcoma is one of the most frequent primary bone sarcoma. The most affected subjects are adults around the fifth-sixth decades of life. Central chondrosarcoma (CS) is graded on a scale of 1 to 3 according to histological criteria. These tumors can be divided into low-grade (Grade 1) and high-grade (Grade 2, Grade 3, and dedifferentiated) chondrosarcomas. However, the histological grade should be correlated with imaging and the clinical presentation for an optimal diagnosis. En-bloc resection has been the most widely used treatment for grade 2-3 CS, whereas for patients with low-grade CS, curettage is safe and effective. This approach requires an accurate preoperative estimation of grade to avoid under- or overtreatment, but prior reports have indicated that both imaging and biopsy do not always give an accurate prediction of grade. It is still debated on what to do in case of a high-grade CS that have been undertreated because of wrong preoperative estimation of grade.
Andrea Sambri, MD PhD
Orthopaedic Oncology and Trauma Surgeon
IRCCS University Hospital Sant’Orsola
Via Massarenti 9 Bologna, Italy
+39 051 214 2680
Member of the European Muscoloskeletal Oncology Society – EMSOS
Italy Country Delegate of the European Bone and Joint Infection Society – EBJIS
Total Femur Replacement: Functional Outcome, Clinical Results and Gait Analysis.
Dear colleagues, hereby we invite you to participate in the multicentric retrospective study “Total Femur Replacement: Functional Outcome, Clinical Results and Gait Analysis”.
Total femur replacements (TFR) are very rare and associated with high complication and failure rates. To our knowledge, there is no literature regarding further specific functional analysis including gait analysis for patients who underwent a total femur replacement. Due to patients’ higher demand for a good functional outcome, and a better oncological outcome, we believe there is a need for further investigation and for larger data in order to draw conclusions. Outcomes of total femur replacements for oncological or non-oncological indications will be analyzed. A competing risk and event analysis of the protheses survival will be performed. Additionally, gait analysis will provide further insight about functional performance.
Dr. Marisa Valentini
Medical University of Graz
Primary leiomyosarcoma of bone (LMSoB)
Primary leiomyosarcoma of bone (LMSoB) is a rare subtype of bone sarcomas, accounting for less than 0.7% of all malignant bone tumours. The aim of this study is to extend existing data on patients with LMSoB with further cases one to increase the dataset to a sufficient number of patients, eventually allowing to draw conclusions on behavior and treatment response of this extremely rare tumor entity.
Dr. Maya Niethard
Clinic for Tumor Orthopedics, Helios Clinic Berlin-Buch
Schwanebecker Chaussee 50
Periprosthetic Joint Infection in Megaprostheses following Bone Sarcomas
Infection rate in end-prosthetic reconstruction ranges from 3 to 30%, with even 60% for revision arthroplasty. Due do use of neoadjuvant chemotherapy, bone sarcoma patients are at particularly high risk to develop periprosthetic joint infections (PJI). This EMSOS study aims at systematically collecting data from patients treated for PJI of megaprostheses following reconstruction for bone sarcoma surgery.
Dr. Andrea Sambri
Management of Skeletal Metastases
The current retrospective study aims at obtaining data related to anatomical location and extent, radiological presentation and choice of surgical treatment policy of metastatic bone disease located at the shoulder girdle, upper and lower extremities, and pelvic girdle.
Based on the data ascertained, the clinical and radiological presentation as well as treatment strategy of metastatic bone disease with regards to histological type and medical history will be analysed.
Prof. Jacob Bickels
Prof. Domenico Andrea Campanacci
A retrospective study of local relapse after high grade osteosarcoma
Aim of this study is to analyse the modalities of diagnosis of LR in high-grade osteosarcoma, pattern of recurrence, treatment of LR and factors influencing post-LR survival (PLRS) focusing on the role of second line chemotherapy, margins and type of surgery
Emanuela Palmerini, Bologna
PROJECT: Tumors at the elbow – clinical and oncological results after resection and endoprosthesis replacement
Invitation to participate the study
Dear colleagues, hereby we invite you to participate in a multicentric retrospective study “Tumors at the elbow – clinical and oncological results after resection and endoprosthesis replacement”.
Bone and soft tissue tumors involving the elbow are very rare. There is a limited knowledge about clinical and oncological results of distal humerus and/or proximal ulna resection and endoprosthetic elbow reconstruction: in the last two decades only a few publications analyzed this problem, including per study at average about 20 patients. These studies include numerous various parameters (different implants, various diagnosis…), making the task of summarizing the results not easy.
Dr. Marko Bergovec
EMSOS study “Sarcoma during Pregnancy”
Malignancy during pregnancy is a very rare entity with an estimated incidence of 1/1000 pregnancies. Individual therapeutic customization is the only choice of treatment with respect to the health of the mother, and her child.
The occurrence of sarcoma during pregnancy is even more exceptional, with about 140 reported cases in the accessible literature. 60% is reported as primary soft tissue sarcomas, 40% as primary bone sarcomas. No true systematic study has been undertaken to investigate the whole diagnostic, therapeutic and prognostic concept of these sarcomas during pregnancy as an ‘entity’.
University Department of Experimental Pathology, Vrije Universiteit Brussel, Belgium.
Prof. dr. Ramses Forsyth, director (firstname.lastname@example.org).
Mazabraud Syndrome is a very rare combination of fibrous dysplasia (FD) and intramusculary myxomas. Both entities are caused by activating GNAS-mutations and while FD is often diagnosed at a younger age, myxomas tend to arise later, often in the fourth or fifth decade of life, and are localized adjacent to FD lesions in the majority of the patients. The myxomas can lead to mechanical problems and symptoms of pain. Excision of the myxomas has been proposed, although outcome of surgical interventions and whether there are predictive factors for recurrence of the myxomas remains eluded.
If you need any assistance please contact Bas Majoor, email@example.com
EMSOS Study "Angiosarcoma"
Angiosarcoma is the malignant end of the spectrum of vascular tumors, spanning diagnosis including hemangiomas, hemangioendothelioma, well-differentiated and poorly-differentiated angiosarcoma.
Angiosarcoma of bone is rare, accounting for <1% of all primary bone sarcomas and it is associated with a poor prognosis. Although any age can be affected, the incidence is highest between 50 and 70 years of age.
Angiosarcoma of bone may present as unifocal or multifocal disease. The most common locations of unifocal tumor are the long and short tubular bones, followed by the pelvis, and trunk.
Histologically, angiosarcomas of bone are composed of anastomosing vascular channels lined by atypical endothelial cells with enlarged nuclei, prominent nucleoli, and increased mitoses. Inflammatory cells, mostly eosinophils, may be present.
Given the rarity of angiosarcoma of bone, the literature is limited regarding treatment and outcome of patients with this tumor.
The role of chemotherapy and prognostic factors for these patients remain unclear.
Under the auspices of the EMSOS, a retrospective study has been launched with the aim of improving our knowledge on the natural history of the tumor and on prognostic and predictive factors of survival.
Stefano Ferrari MD
SSD Chemioterapia dei Tumori Muscoloscheletrici
Istituto Ortopedico Rizzoli – WWW.ior.it
Via Pupilli 1, 40136 Bologna. Italy
DGOOC / EMSOS study "Clear cell sarcoma"
Osteosarcoma after retinoblastoma
Sebastian Asaftei, Torino / firstname.lastname@example.org